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Introduction
Inflammation is often a sign of a healthy
immune system— contrary to the unregulated
propagation and damage caused by irregular,
chronic inflammation present in
neurodegenerative diseases. Regular
inflammation is a means by which the body
creates an environment inhospitable by
microbes, such as bacteria or viral particles.
The most apparent physical representation of
inflammation in the body is a fever— the body’s
method of increasing the blood pressure to
allow the delivery of immune cells to the site of
infection more rapidly and efficiently.
A fever, however, is a response that is largely
the first resort, meaning that it is a natural
defense considered to be part of the innate
immune system’s response to foreign
invaders/bodies. The entire immune system is
split into two divisions: the innate and the
adaptive. These two divisions are still largely
intertwined, and immunologists today still don’t
have a complete explanation for all the ways
that the two parts of the immune system work
together. Fever is only one example of
inflammation that occurs in the body, but it is
inflammatory responses related to fever that—
when not properly regulated by the body’s
homeostatic mechanisms—can lead to
neurodegenerative diseases, such as
Parkinson’s disease (PD) or Alzheimer’s
disease (AD).
Immunotherapy is a fairly new field of science
and is rapidly taking over the field of alternative
medicine in areas of research such as cancer
and allergies. This poster focuses on the recent
applications of immunotherapy to prevalent
neurodegenerative diseases such as PD and
AD. Other neurodegenerative diseases that are
not discussed in this poster but are notable
include Amyotrophic Lateral Sclerosis (ALS or
Lou Gehrig’s disease), Motor Neuron disease
(MND), and Huntington’s disease (HD).

Current Research
The most common immunotherapeutic
approaches to neurodegenerative diseases
involve the use of antibodies (most commonly,
the IgG antibody subtype) in both passive
(antibodies made prior to injection) and active
(immune system given the
parameters/antigens to make own antibodies)
immunization of the patient. Both of these
methods utilize the innate and adaptive
branches of the immune system to achieve a
reduced propagation of symptoms associated
with neurodegenerative diseases, such as
plaque aggresomes or oxidative stress.

Figure #2: Passive vs. Active Immunization in an AD Model
Image Source: Wisniewski, T., & Goñi, F. (2015). Immunotherapeutic Approaches for Alzheimer’s
Disease. Neuron,85(6), 1162-1176.

Research done with immunomodulation, or the
modification of the immune response (in this case,
through the use of plant-based derivatives that
alter cytokine production) is largely cellular-based
currently and usually involves cocultures of
immortalized mouse microglial cells (such as BV-2
or IMG) and mouse hippocampal neuronal cell
lines (such as HT22); using human monocytes
with this research model is on the rise.

Figure #1: Routes of Passive Immunization in Neurodegenerative Disease Models
(Anti-amyloid beta). Plaque disaggregation, FcR mediated phagocytosis, and the
Peripheral Sink Mechanism are all methods that involve the injection of antibodies to the
protein amyloid-beta (anti-Aβ IgGs). Plaque disaggregation involves Fab-fragment binding of
Anti-Aβ to Aβ protein and subsequent proteasomal degradation of these marked antigens.
FcR Mediated Phagocytosis involves the recruitment of microglial cells to Aβ aggresomes
plaques and degradation via activation of the FcR microglia receptor sites by IgGs.
Peripheral sink mechanism involves flushing/off-loading of CSF (cerebral spinal fluid) Aβ
populations through the blood-brain barrier, where antibodies on the other side can mark the
proteins for immune response. Image Source: Montoliu-Gaya, L., & Villegas, S. (2018).
Immunotherapy for neurodegenerative diseases: The Alzheimers disease paradigm. Current
Opinion in Chemical Engineering,19, 59-67.

Other methods include using molecules of a
plant-based derivative as a treatment to reduce
the chronic inflammation that the
overabundance of cytokines such as the
interleukins (IL-6 or IL-8), interferon-γ (IFN-γ),
and tumor necrosis factor-β (TNF-β) cause due
to microglial overactivation.

Conclusions
Immunotherapy targets– whether indirectly or
directly– the internal environmental of the CSF.
Microglial cells are macrophage derivatives and
act as the ‘clean-up crew’ for the brain,
sweeping debris from the surrounding area after
a successful defense. Plaque formation triggers
microglial activation, which triggers the release
of inflammatory cytokines such as IL-6, TNF-β,
etc. In normal amounts, these cytokines simply
act as ways of communication between
neuronal cells. However, when the microglial
population surrounding an area is consistently
activated due to the accumulation of
aggresomes, the cytokines can cause chronic
inflammation of the surrounding area, inflaming
neural bodies and causing physical damage to
both neuroglia and neuron cells alike. It is this
mechanism that often causes or helps worsen
many neurodegenerative diseases such as AD
or PD. It is also this area that is of intense focus
in the field of immunotherapy when researching
the many factors causing neurodegenerative
diseases.
Immunotherapy is currently on the rise because
research in this field is not only applicable to
neurodegenerative diseases but also cancer,
allergies, organ transfers (through antibody
treatment and MHCI/MHCII) and so on.
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